AACR Meeting Presentations
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday)
Blueprint Medicines Corporation (NASDAQ: BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday)
Mirati Therapeutics, Inc. (NASDAQ: MRTX) and
BeiGene, Ltd. (NASDAQ: BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati s sitravatinib plus BeiGene s tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday)
Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday)
Tricida to Present at the Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20
th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows progression of CKD in patients wi
Published: Apr 08, 2021
BOSTON, April 08, 2021 (GLOBE NEWSWIRE)
Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., founder, president, and CEO of Akouos, will participate in a fireside chat at the 20
th Annual Needham Virtual Healthcare Conference on Wednesday, April 14 at 4:30 p.m. ET.
A live webcast of the fireside chat will be available on the investors section of the company’s website at www.akouos.com. To access the webcast, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akouos’s website for 14 days following the conference.
Anika to Participate in the 20th Annual Needham Virtual Healthcare Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Search jobs Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
NASHVILLE, Tenn. (BUSINESS WIRE) Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 12-15.
President and Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, April 13, at 7:15 a.m. PT / 10:15 a.m. ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company s website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.